Avadim Technologies Receives Notices of Allowance From U.S. and Japan Patent Offices for Inventions Related to Reducing Catheter Associated Urinary Tract Infections (CAUTI)

ASHEVILLE, N.C., April 23, 2018 -- Avadim Technologies, Inc. (“Avadim”), the Bionome Therapies^TM life sciences company, announced today that its patent applications have been allowed in the U.S. and Japan relating to a method for reducing the incidence of catheter associated urinary tract infections, or CAUTI. 

Steve Woody, Chairman and CEO of Avadim, stated, “We are pleased that the USPTO has allowed our patent application Method for Maintenance of Urethral Catheters, Serial No. 14/629,320, which was filed on February 23, 2015.  We have also received an allowance of our corresponding patent application in Japan on the composition for use in the method and already have an issued patent in Luxembourg.  We are continuing to seek corresponding patents in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel and Mexico and additional patents as warranted.  Advancing our intellectual property portfolio globally has been our long-term strategy and today we have made yet another significant step forward.”

The Notice of Allowance in the U.S. relates to a method for insertion, maintenance and removal of urethral catheters in humans and other mammals.  Avadim’s method includes protocols it developed for applying Avadim’s Theraworx® Protect^TM brand skincare solutions.  Practice of the method reduces and even prevents the incidence of CAUTI.  In addition to sterile procedures currently practiced, or as may be practiced in the future in connection with catheter use, the method includes the steps of applying Avadim’s Theraworx® Protect^TM brand skincare solution to the perineum, meatus and contiguous mucosa surrounding the insertion site before insertion, after insertion, periodically during the period of indwelling, and before and immediately after removal of the catheter. Theraworx® Protect^TM skincare solution is typically applied after each incidence of incontinence and, optionally, on a periodic basis after catheter removal until the threat of an infection associated with catheter use has passed, typically at least about five to seven days and up to thirty days after removal. The solution’s pH is desirably from about 4.4 to 5.5.

About Avadim Technologies Inc.:
Based in Asheville, NC, Avadim is a rapidly growing life sciences company built around the concept of serving. With a mission to change lives and transform communities, Avadim identifies unmet needs and addresses them in unique ways through continued R&D with its Theraworx® brand family of skincare solutions. The company offers a portfolio of advanced, safe solutions for infection prevention and physical performance and has a strong pipeline across a broad range of health, performance and wellness areas. 

Avadim Technologies Inc. Contacts:
David Fann, President
828.251.7111 Office
904.251.4910 Cell
[email protected]

Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
[email protected]

Avadim Technologies Inc.
81 Thompson Street
Asheville, NC 28803
www.avadimtechnologies.com

Investor Relations:
KCSA Strategic Communications
Valter Pinto
212.896.1254
[email protected]
www.kcsa.com